Dapagliflozin propanediol belongs to the class of orally administered antidiabetic agents designated as sodiumglucose cotransporter 2 (SGLT2) inhibitors.
Dapagliflozin is a small-molecule inhibitor of SGLT2 that has been shown to be highly selective for SGLT2 compared with other SGLT family members and to have no off-target interactions in an in vitro screen of more than 330 receptors, enzymes, ion channels, and transporters[1].
Dapagliflozin demonstrates good oral bioavailability, has a high volume of distribution, and has an in vivo metabolite profile that is qualitatively similar between preclinical species and humans. Both non-clinical and clinical assessments have shown dapagliflozin to have a highly favorable safety profile that is consistent with its simple mechanism of action, with no off-target effects observed[1].
[1] Reilly TP, et al. Diabetes Ther. 2014, 5(1):73-96.